NMPA Submission Phase – 心脏生物科技 (CBSC)

CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

Jan 15

Cardiac Biotech

心脏生物科技解决方案激活MyCardia AT中国生产流程并进入NMPA最终申报阶段

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.

News

0 Comments

How can we help you?

Tell us what you are interested in.

Contact Us